Neflamapimod: Ph IIa Study 303 data

The double-blind, U.S. Phase IIa Study 303 in 8 evaluable patients ages 60-85 with mild cognitive impairment (MCI) due to

Read the full 202 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE